Literature DB >> 18437679

Cardiac ischemia and reperfusion in spontaneously diabetic rats with and without application of EGb 761: I. cardiomyocytes.

Rick Schneider1, Klaus Welt, Wolfram Aust, Heinz Löster, Günther Fitzl.   

Abstract

Diabetic cardiomyopathy is known to result in increased mortality after ischemic events. Permanently increased oxidative stress with formation of oxygen-free radicals plays a key role in the development of specific heart muscle disease. Associated lesions include structural alterations to cardiomyocytes. Antioxidative treatment in addition to the usual insulin substitution would seem sensible in preventing or delaying long-term diabetic complications and protecting the myocardium against acute ischemic events. We investigated the effects of radical scavenger Ginkgo biloba extract EGb 761 against diabetes-induced damage to cardiomyocytes and additional ischemia/reperfusion injury in spontaneously diabetic BioBreeding/Ottawa Karlsburg (BB/OK) rats, as a model of diabetic myocardium infarction. Morphological and morphometric parameters of heart muscles were analyzed by light and electron-microscopic techniques. We used immunohistochemistry to evaluate parameters of oxidative stress (superoxide dismutase [SOD]) and inducible nitric oxide synthase (iNOS) protein expression. Our results indicated that A) Diabetic myocardium appears more vulnerable to ischemia/reperfusion damage concerning ultrastructure of cardiomyocytes (sarcomeres, vacuoles, mitochondria), expression of antioxidative enzymes (CuZnSOD, MnSOD), and iNOS than normal myocardium; B) Pre-treatment of diabetic myocardium with EGb and additional ischemia/reperfusion leads to a relative improvement in myocardial ultrastructure compared to unprotected myocardium. In summary, EGb appears to be promising as an adjuvant therapeutic drug in diabetics with respect to ischemic myocardium injury. It may contribute to the prevention of late diabetic complications in diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437679     DOI: 10.14670/HH-23.807

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  Chinese Expert Consensus on Clinical Application of Oral Ginkgo biloba Preparations (2020).

Authors:  Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2021-01-09       Impact factor: 1.978

Review 2.  Oxidative stress and myocardial injury in the diabetic heart.

Authors:  David M Ansley; Baohua Wang
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

Review 3.  Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

Authors:  Christina Voulgari; Dimitrios Papadogiannis; Nicholas Tentolouris
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

4.  Ginkgo biloba extract (EGb761) inhibits mitochondria-dependent caspase pathway and prevents apoptosis in hypoxia-reoxygenated cardiomyocytes.

Authors:  Jiangang Shen; Waisin Lee; Yong Gu; Yao Tong; Peter Cw Fung; Li Tong
Journal:  Chin Med       Date:  2011-02-23       Impact factor: 5.455

Review 5.  Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview.

Authors:  Divya Singh; William C Cho; Ghanshyam Upadhyay
Journal:  Front Physiol       Date:  2016-01-26       Impact factor: 4.566

6.  Assessment of the Protective Role of Prenatal Zinc versus Insulin Supplementation on Fetal Cardiac Damage Induced by Maternal Diabetes in Rat Using Caspase-3 and KI67 Immunohistochemical Stains.

Authors:  Ahmed S Shams; Mona H Mohammed; Mona M Loka; Gamal M Abdel Rahman
Journal:  Cardiol Res Pract       Date:  2016-01-27       Impact factor: 1.866

7.  The effect of levosimendan on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats.

Authors:  Hasan Ali Kiraz; Fatih Poyraz; Gülay Kip; Özlem Erdem; Metin Alkan; Mustafa Arslan; Abdullah Özer; Volkan Şivgin; Faruk Metin Çomu
Journal:  Libyan J Med       Date:  2015-01       Impact factor: 1.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.